Healthcare is going through a major transition phase and is ripe for innovation, that much we know for sure. We also know that innovation comes from talented leadership, backed by smart investors.
iSelect is working with industry experts to accelerate this transition, partnering with leading medical professionals and institutions to help make promising healthcare innovations a reality. Our approach is based around the simple idea that true change in health and medicine is going to come from the inside, from the doctors, researchers, and other healthcare professionals who are doing this work every day.
We want to partner with them. We want to support their ideas. We want to help their companies grow.
We work with major research centers to find the most promising opportunities, and we work with doctors to match our diligence and deal sourcing with their medical expertise to back the select few companies with the most promise. So far, this includes companies focused on chronic pain, cancer, epilepsy, pulmonary fibrosis and more.
They are the experts in healthcare. iSelect is the expert in venture investing. Together we can solve this problem.
Selection Team
Bryce Rutter
B2B Technology Team, Healthcare Team
Dr. Rutter is founder and CEO of Metaphase Design Group, a design firm serving industrial, commercial and consumer product and packaging clients internationally. He is an acknowledged specialist in ergonomic product design and a leading worldwide expe …
Michael Nichols
B2B Technology Team, Healthcare Team
Michael Nichols, Ph.D. presently serves as an investor and C level management for various startups. He serves as an Analyst for Vinlogx, a platform that acquires, stores, and analyses internal vehicle information enabling solutions across multiple auto …
Chas Eggert
Agriculture Team, Healthcare Team, Resource Efficiency Team
Charles R. (Chas) Eggert has 40 years of experience in the specialty chemicals industry with a proven track record of creating value for startups and large global businesses. Chas is an operating partner focused on specialty chemical investments with A …
David Christenson
David Christenson joined BioGenerator as an Entrepreneur-in-Residence in 2015 focusing primarily on healthcare and specifically in information technology, care delivery and payment, and services. Over a 30-year career, David has developed substantive b …
Michael Beat
Presently leading Arch Cancer Care as Medical Director, Dr. Beat is a local expert in collaborative prostate cancer management. At a national level, he contributes to physician leadership committees within the US Oncology Network. Having earned an exec …
Bobby Sandage
Bobby Sandage is currently President and CEO of Euclises, Chairman of the Board of Immunophotonics, member of the board of directors of EDIS, and a member of the Cultivation Capital life sciences fund investment committee. He was formerly President and …
Melissa Walker
A regulatory professional with over 27 years of experience in the medical products industry, Melissa currently serves as Founder, President and CTO at Graematter, Inc. and Senior VP Regulatory at Topera. Specialties include regulatory intelligence rese …
Dr. Renato Cataldo
B2B Technology Team, Healthcare Team
An accomplished senior executive with start-ups, growth, and turn-around organizations, Renato developed a healthcare technology corporation, HealthTech Solutions, from a small start-up of 3 people to a national provider of technical solutions to healt …
iSelect Companies
Gila is developing a treatment for obesity using naturally occurring hormones (PYY) known to induce satiety, leading to weight loss. Gila is developing formulations to be applied to the tongue prior to meals, which have successfully induced satiety in animal testing without causing the nausea like symptoms associated with injectable and other formulations.
Learn more… 
Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Previs Audio Spectral Analysis Technology (PASAT). The first application, PrevisEA, is a noninvasive, disposable, self-contained device that is clinically proven to predict postoperative ileus (POI) in surgical patients.
Learn more…
Zumbro Discovery is a biotech company developing novel peptides for the treatment of resistant hypertension (RH), a condition characterized by a combination of cardiovascular, kidney and adrenal gland complications. RH is an indication with no approved drugs that affects 12% of US hypertensives, or 9 million Americans, and an estimated 300 million people worldwide.
Learn more…
Cofactor Genomics uses proprietary RNA sequencing technology and machine learning algorithms to diagnose disease. RNA serves as a real-time barometer of a person’s health, as opposed to DNA which remains little changed throughout a person’s life and whose analysis is estimated to diagnose less than 5% of diseases. Compared to current methods, Cofactor’s patent pending RNA isolation technology allows the Company to detect specific RNA molecules from low-quality tissue samples, making 100x more patient specimens available for analysis.
Learn more…
Indalo Therapeutics (formerly known as Antegrin Therapeutics, Inc.), based in St. Louis, MO is a biopharmaceutical company developing and testing novel compounds that inhibit the development of pulmonary (lung) fibrosis and other fibrotic diseases by inhibiting proteins that are the key drivers of the fibrotic process. Uncontrolled, fibrosis can cause diseased organs to stop functioning.
Learn more…
Euclises Pharmaceuticals is developing and testing novel cyclooxygenase-2 (COX-2, an enzyme responsible for inflammation and pain) inhibitors designed to increase the anti-cancer potency and effectiveness of chemotherapy safely, offering new treatment options for patients suffering from colorectal, non-small cell lung and pancreatic cancers.
Learn more…
Neuros Medical, Inc., a Cleveland, Ohio based neuromodulation company, is focused on developing proprietary therapies for unmet needs to patients worldwide. The company’s patented platform technology, Altius® Electrical Nerve Block, is focused on elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.
Learn more…
Tansna Therapeutics, Inc., based in St. Louis, MO, is developing and testing anticonvulsant drugs for the treatment of epilepsy. Worldwide, at least 50 million people suffer from epilepsy, 30% of whom are unable to achieve adequate seizure control using existing medications. Tansna’s proprietary anticonvulsant compounds have been shown in animal testing to prevent seizures in such otherwise therapy-resistant patients.
Learn more…
Read More from iSelect
DNA, RNA and the Coming Reality of Personalized Medicine
Medicine has always been a science of averages. Most people in the population tend to suffer from most of the same diseases, and most of those diseases respond to most of the same treatments. If one therapy doesn’t work, doctors always have other drugs and other...
read more
Sound Waves, Predictive Analytics and the Future of Medical Diagnosis
It began as a straightforward, everyday procedure. The patient, a 34-year-old man, entered the hospital for abdominal surgery to treat his persistent colitis, a disease typified by the inflammation of the inner colon. The treatment itself was unremarkable and the...
read more
Innovation Anarchy: Doctor, Please Stop, You’re Killing Me!
I learned three important lesson about innovation early in my career as an engineer at McDonnell Douglas. It was 1989 and I was assigned to work on the Navy’s F/A-18 Hornet, a carrier-based fighter jet. Originally designed in 1976, the F/A-18 was planned to remain...
read more
iSelect Portfolio: Neuros Medical Closes $20 Million Funding Round
Neuros Medical, part of the iSelect healthcare portfolio since 2016, closed a $20 million Series AA financing round, led by U.S. Venture Partners and joined by iSelect, Boston Scientific, Aperture Venture Partners, Osage University Partners, and JumpStart, Inc. Neuros...
read more
Fibrosis: One of the Most Common Disorders in Modern Medicine
Fibrosis is a category of diseases that covers a lot of bases, striking everything from the lungs, to the heart, to the skin and more. And its causes are just as diverse, ranging from diabetes, to environmental factors, to genetics and even certain medications. At its...
read more
Resistant Hypertension: Ending the Death Sentence
Physicians have been fascinated with blood and the circulatory system for hundreds of years. Records dating back to early Roman times prove that bloodletting was in wide use as a treatment for disease at least 2,000 years ago, and leeches have been used in medicine...
read more
Cofactor Genomics: RNA Is About to Make Personalized Medicine a Reality
By David Messina, PhD This is an amazing time to be in biology. In fact, I like to say that right now we’re in a place that’s a lot like where personal computers were in 1987. In those days, PCs were pretty limited in what they could do. They still ran off of floppy...
read more
Immunophotonics, SAKK Move Forward with Research Collaboration
Cancer care is entering a new age, transitioning from treatments that attack both cancerous and healthy cells at the same time, to more targeted, specialized therapies that address the root cause of cancer itself without damaging surrounding tissues. Biotech company...
read more
Gila Therapeutics: New Solutions for the Obesity Crisis
Obesity is the single largest health crisis facing the world today. More than one billion people worldwide are overweight or obese, accounting for 38% of the population. In the U.S., a full 68% of adults, or some 200 million people, are overweight. On average, obese...
read more
House Calls Are Back: How Epharmix Is Revolutionizing Healthcare
There is massive consolidation occurring in the healthcare space right now, and as a result hospital systems are acting almost like private equity groups. They're sucking up all of these once-independent primary care providers and are distributing all of the...
read more
